Novartis seeks leadership with Cosentyx

6 Nov 2017

For the first time for any biologic, data show almost 80% of ankylosing spondylitis patients on Cosentyx have no radiographic progression of the spine at 4 years.

Novartis has announced new long-term Cosentyx (secukinumab) data for patients with ankylosing spondylitis (AS). This study is unique as these data show, for the first time with any biologic, that almost 80% of AS patients treated with Cosentyx have no radiographic progression (mSASSS <2) of the spine at 4 years. The new data also confirm sustained improvement in signs and symptoms in almost 80% of patients, while Cosentyx delivers a favorable and consistent safety profile.

Novartis seeks leadership with Cosentyx

"The key finding of these data is that patients treated with Cosentyx may now have the opportunity to maintain their mobility for a longer time. This is very important as ankylosing spondylitis is a crippling condition that can impact people in their twenties when they still have many decades of their life ahead of them," said Vas Narasimhan, Global Head, Drug Development and Chief Medical Officer, Novartis. "For the first time for any biologic, Cosentyx shows that almost 80% of patients had no radiographic progression for as long as 4 years. These data demonstrate the potential of Cosentyx to help patients live with less pain and retain their mobility for longer."

These new long-term data add to a growing body of evidence demonstrating the unique position of Cosentyx with lasting efficacy and proven safety across AS, psoriatic arthritis (PsA) and moderate-to-severe psoriasis. Cosentyx is the first and only IL-17A inhibitor approved for AS. Cosentyx is a highly targeted biologic for first-line use in AS, a chronic inflammatory disease that can lead to prolonged pain and mobility loss.

Read More

Related tags

Research & Development

Related news

Plasticell wins military contract to develop regenerative medicines for the battlefield

Plasticell wins military contract to develop regenerative medicines for the battlefield

4 Sep 2018

Company to use its combinatorial stem cell screening platform to develop technologies for the conversion of pluripotent stem cells into platelets.

Read more 
New biopharmaceutical testing laboratory to open in Geneva

New biopharmaceutical testing laboratory to open in Geneva

28 Aug 2018

SGS's expansion will enable the service provider to offer a full ICH Q6B physico-chemical characterization of biological products.

Read more 
Exosome isolation manufacturing and characterization

Exosome isolation manufacturing and characterization

13 Aug 2018

New service to reliably and reproducibly isolate exosomes from almost any biofluid.

Read more 
Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines

Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines

8 Aug 2018

Company moves away from manual processing in favour of automated, scalable platforms.

Read more 
A new era for migraine patients

A new era for migraine patients

6 Aug 2018

EU approves Novartis's Aimovig, a first-of-its-kind treatment specifically designed for migraine prevention.

Read more 
WuXi STA and Antengene sign development and manufacturing agreement

WuXi STA and Antengene sign development and manufacturing agreement

24 Jul 2018

WuXi STA chosen for its end-to-end CMC platform for new drug development.

Read more 
ProBioGen and Pionyr initiate 2nd immuno-oncology contract development and manufacturing project

ProBioGen and Pionyr initiate 2nd immuno-oncology contract development and manufacturing project

18 Jul 2018

Parallel cell line development and analysis will allow for optimal cell line selection while compressing the development timeline.

Read more 
New screening company exploits the latest advances in microfluidics and 3D culture

New screening company exploits the latest advances in microfluidics and 3D culture

19 Jul 2018

The ability to micro size drug-cell interactions will allow pharmaceutical and biotech companies to do 100x more testing for the same money spent as well as increasing productivity.

Read more 
Natural lipid acts as potent anti-inflammatory

Natural lipid acts as potent anti-inflammatory

10 Jul 2018

Scientists see therapeutic potential against bacteria, viruses.

Read more 
Plasticell leads gene therapy manufacturing consortium

Plasticell leads gene therapy manufacturing consortium

3 Jul 2018

Consortium to develop advanced technologies for the manufacturing of ex vivo gene therapies.

Read more